期刊
MEDICAL HYPOTHESES
卷 147, 期 -, 页码 -出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.mehy.2021.110486
关键词
Cardiology; Covid-19; Cytokine; Neprilisin; Sacubitril; Sars-CoV-2
In the absence of effective antiviral drugs or vaccines against SARS-CoV-2, it is crucial to explore new treatment options from existing drugs on the market. Recent hypotheses suggest that a combination of AT-1 receptor antagonists and neprilysin inhibitors may provide clinical benefits to patients with severe COVID-19 infection and cardiac involvement.
On March 11, 2020 the World Health Organization (WHO) declared the state of global pandemic caused by the new SARS-CoV-2 (COVID-19). To date, no antivirals directed against SARS-CoV-2 or effective vaccines to combat the viral infection are available. Severe acute respiratory syndrome caused by SARS-CoV-2 is treated empirically with antivirals, anti-inflammatory, anticoagulants. The approval of an effective vaccine still takes time. In this state, it may be useful to find new therapeutic solutions from drugs already on the market. Recent hypotheses suggest that the use of AT-1 receptor antagonists (ARB) in combination with neprilisin inhibitors (NEPi) could indirectly provide clinical benefits to patients with SARS-CoV-2 and cardiac involvement. In this article we investigate and describe a possible innovative pharmacological approach for the treatment of the most severe stages of COVID-19 infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据